linjc16/ctgov huggingface dataset:
The China Laparoscopic Right Hemicolectomy SNAPSHOT

Study Overview
=================
Brief Summary
-----------------
The main objective is to explore the current practice of right hemicolectomy for colon cancer located in the ascending colon and hepatic flexure in selected Chinese high quality and high volume centres. This study will identify a potential area to improve the level of standard care and serve as a reference cohort to which planned standardization and addition of innovative aspects can be compared to

Official Title
-----------------
The China Laparoscopic Right Hemicolectomy SNAPSHOT

Conditions
-----------------
Right Hemicolectomy, Colon Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Segmental right sided hemicolectomy (including extended) Cancer stage 1-3 (CT-staged) No prior abdominal surgery Exclusion Criteria: Stage cT4b, perforated disease Acute obstruction Emergency surgery Right hemicolectomy or ileocaecal resection as part of a large procedure such as subtotal colectomy or panproctocolectomy Patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post-operative anastomotic leakages | Number of post-operative anastomotic leakages within 30 days. | 1 month |
HRV and Pain Intensity

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to explore the association between pain intensity and heart rate variability in patients with chronic pain.

Official Title
-----------------
The Association Between Pain Intensity and Heart Rate Variability in Chronic Pain Patients.

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Other: Heart Rate Variability
* Other: Pain intensity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with chronic pain for at least 3 months Age > 18 years Patient has been informed of the study procedures and has given written informed consent Patient willing to comply with study protocol Exclusion Criteria: Healthy patients or patients with acute pain. Evidence of an active disruptive psychiatric disorder that may impact perception of pain, and/or ability to evaluate treatment outcome as determined by investigator Patients were excluded if they had one or more coexisting conditions known to affect HRV analysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic pain<br>Patients with chronic pain, regardless of the cause of the pain. | Other: Heart Rate Variability<br>* Heart Rate Variability will be measured with a Polar device.<br>Other: Pain intensity<br>* Pain Intensity will be measured with a Numeric Rating Scale and Visual Analogue Scale<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart Rate Variability | Heart Rate Variability will be measured with a Polar device during a 5 minute recording. | During study visit, cross-sectional, once, during 5 minutes. | 
| Pain Intensity with Numeric Rating Scale | Pain Intensity will be measured with a Numeric Rating Scale. | During study visit, cross-sectional, once. | 
| Pain Intensity with Visual Analogue Scale | Pain Intensity will be measured with a Visual Analogue Scale. | During study visit, cross-sectional, once. |
Development of New Prenatal Diagnostic Tests From Maternal Blood

Study Overview
=================
Brief Summary
-----------------
After extraction of the cell-free DNA circulating in maternal plasma, we aim at developing new techniques for fetal DNA enrichment to perform fetal gender determination, and indirect diagnosis of inherited diseases like Cystic Fibrosis, Huntington Disease, Myotonic Dystrophy, B-Thalassaemia...

Official Title
-----------------
Development of New Prenatal Diagnostic Tests From Maternal Blood

Conditions
-----------------
Hereditary Diseases

Intervention / Treatment
-----------------
* Genetic: Blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mother and father-to-be both older than 18 years old Mother and father-to-be affiliated to social security Mother and father-to-be have good understanding of the protocol Pregnancy of the mother-to-be attested Exclusion Criteria: Mother and father-to-be are younger than 18 years old Mother and/or father-to be refusing to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Blood samples|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of fetal gender and genotype determination out of maternal blood |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fetal DNA, prenatal diagnosis, maternal plasma, Diagnostic potential of cell-free fetal DNA circulating in maternal blood
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if treatment with the ELAD Bioartificial Liver Assist Device is beneficial to patients in Acute Liver Failure either as a bridge to liver transplant or bridge to native liver recovery.

Detailed Description
-----------------
Current treatment with modalities in Acute Liver Failure still carry unacceptable morbidity and mortality. It is hoped that by intervening with ELAD a patient will have an opportunity to be bridged to transplant or to avoid transplantation and to have their native liver recover.

Official Title
-----------------
Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure

Conditions
-----------------
Fulminant Hepatic Failure

Intervention / Treatment
-----------------
* Biological: ELAD
* Other: Standard of care (Control)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Clinical diagnosis of Fulminant Hepatic Failure with encephalopathy, and coagulopathy Weight not less than 40 kilograms Not listed for organ transplant, but no medical contraindications for transplant Exclusion Criteria: Listed for organ transplant at stud entry History of jaundice for greater than 28 days at screening Liver dysfunction due to trauma Concomitant serious disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ELAD<br>Treatment with ELAD, extracorporeal liver assist system and standard of care | Biological: ELAD<br> <br> * Other names: Extracorporeal Liver Assist Device;|
| Other: Standard of care (Control)<br>Standard of care for patients with fulminant hepatic (liver) failure | Other: Standard of care (Control)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects reaching 30-Day survival | 30-day survival | Study Day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-day transplant-free survival |  | Study Day 30 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fulminant Hepatic Failure
Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to built the standard of Chinese Traditional Medicine test for Post percutaneous coronary artery intervention and coronary artery bypass graft，also for acute coronary syndrome，according to the multi-site、random large sample test.

Official Title
-----------------
Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease

Conditions
-----------------
Percutaneous Coronary Artery Intervention, Coronary Artery Bypass Graft, Acute Coronary Syndrome

Intervention / Treatment
-----------------
* Drug: cipher prescription 1
* Drug: cipher prescription 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age40～75 angina or CAD patient deficiency of heart-QI and blockage of phlegm and blood stasis in chinese medicine 1 week after operation，or 1week after drainage tube extraction for CABG sign a informed consent Exclusion Criteria: severe cardia failure severe renal inadequacy complicating with malignant tumor,reactive alimentary tract hemorrhage and haematological systemic disorder etc. psychotic pregnant,lactation

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: managed group<br> | Drug: cipher prescription 1<br>* Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days<br>|
| Placebo Comparator: control group<br> | Drug: cipher prescription 2<br>* Placebo include amidon、bitter principles and diluents bases once daily for 180 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dead |  | 180±3days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular event |  | 180±3days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
percutaneous coronary artery intervention, coronary artery bypass graft, acute coronary syndrome
Metabolic Dynamics During Physical Activity

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to systematically Analyse the metabolome in capillary blood of healthy men and women at rest and during defined standardized physical activity under normobaric normoxia or hypoxia with a specific focus on metabolites and metabolic pattern related to energy metabolism. The metabolome analyses in capillary blood could give us also or more detailed insight into erythrocyte metabolic physiology because it is known for a longer time that the primary metabolism of the erythrocyte reflects its Oxygen Saturation via the glycolytic metabolites / intermediates pattern.

Official Title
-----------------
Metabolic Dynamics During Physical Activity Under Normobaric Normoxia or Moderate Hypoxia - a Pilot Study

Conditions
-----------------
Healthy Men and Women

Intervention / Treatment
-----------------
* Other: running on a treadmill under normoxia or hypoxia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers written informed consent Exclusion Criteria: known cardio-vascular, lung, metabolic, endocrine, hematologic, kidney or neurologic diseases pregnancy, lactating period unability to understand study content and aims and to give written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: running under hypoxia - first<br>running under hypoxia (first day) and normoxia (second day) | Other: running on a treadmill under normoxia or hypoxia<br>* 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%) 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)<br>|
| Active Comparator: running under normoxia - first<br>running under normoxia (first day) and hypoxia (second day) | Other: running on a treadmill under normoxia or hypoxia<br>* 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%) 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in capillary lactate/pyruvate Ratio (dimension-free) | marker for the ratio between anaerobic / aerobic glycolysis | t = 0 min (before exercise); t = 10, 20 and 30 min during exercise; t = 50 and 60 min during recovery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metabolism, metabolome, physical activity, hypoxia
Human Papillomavirus (HPV) Infection in Pregnancy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if maternal infection with human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE), and poor fetal growth.

Conditions
-----------------
Papillomavirus Infections, Pregnancy Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All women presenting for prenatal care at the Hospital of the University of Pennsylvania or affiliated clinics Exclusion Criteria: Multiple gestations Medical conditions such as diabetes, chronic hypertension, renal disease Fetal malformations or chromosomal anomalies Fetal death

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pregnancy complications<br>prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HPV, Pregnancy
Followup of Glenoid Fix Utilizing Auto Bone Graft in Shoulder Replacement

Study Overview
=================
Brief Summary
-----------------
This is a case study to evaluate the adequacy of fixation and functional outcome of the glenoid anchor peg following autologous bone grafting around the prosthesis at the time of implant.

Detailed Description
-----------------
To investigate if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlates with bony apposition on computed tomography scans, decreased radiolucent lines and component loosening, and functional outcomes. We hypothesize that by utilizing autologous bone graft from the resected humeral head, placed around the anchor peg glenoid prosthesis at implantation, there is a low incidence of glenoid loosening. We suggest that the absence of radiolucent lines correlated with excellent shoulder function.

Official Title
-----------------
Computed Tomographic and Functional Follow-up of Glenoid Anchor Peg Component Fixation Utilizing Autologous Bone Graft in Total Shoulder Arthroplasty

Conditions
-----------------
Arthritis

Intervention / Treatment
-----------------
* Procedure: X-rays and CT scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study. Exclusion Criteria: Patients will be excluded if they are unable to comprehend the consent information. Pregnant women will be excluded from this study.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Total shoulder replacement with anchor peg glenoid and autologous bone grafting<br>Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study. | Procedure: X-rays and CT scan<br>* CT Scan x-rays<br>* Other names: No names;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Autologous bone graft, anchor-peg glenoid prosthesis and functional outcomes | To determine if the use of autologous bone graft around the anchor-peg glenoid prosthesis correlate with bony apposition on computed tomography scans, decreased radiolucent lines and component loosening, and functional outcomes. | case study over approximate 3 months time. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glenoid component, radiolucent lines, Glenoid loosening, glenohumeral arthritis, autologous bone graft
Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether cholecalciferol supplementation in patients with chronic heart failure and low vitamin D levels improves: performance at six minutes walking test echocardiographic parameters neurohormonal imbalance

Official Title
-----------------
Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels. A Phase 2 Randomized Double Blind Study

Conditions
-----------------
Heart Failure, Vitamin D Deficiency

Intervention / Treatment
-----------------
* Drug: CHOLECALCIFEROL
* Drug: PLACEBO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heart failure diagnosis according to European Society of Cardiology Guideline criteria Age > 60 years old 25(OH) Vitamin D level < 30 ng/ml Clinical and therapeutic stability for one month (NYHA class II or III) Exclusion Criteria: Chronic use of anticonvulsants or barbiturates, steroids, thiazides, aluminium or magnesium, colestipol or cholestyramine Glomerular filtration rate lower than 30 ml/min/1.73 m2 according to MDRD equation Nephrolitiasis, Sarcoidosis or hypercalcemia Recent (three months) acute coronary syndrome or stroke or major vascular surgery Reduced life expectancy due to other diseases (active neoplasms, liver cirrhosis...)

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CHOLECALCIFEROL<br> | Drug: CHOLECALCIFEROL<br>* Standard guideline based therapy plus cholecalciferol: Loading dose 300.000 U then 50.000 U every month for six months<br>* Other names: DIBASE (ABIOGEN PHARMA);|
| Placebo Comparator: PLACEBO<br> | Drug: PLACEBO<br>* Standard guideline based therapy plus placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SIX MINUTE WALKING TEST DISTANCE |  | six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ECHOCARDIOGRAPHIC PARAMETERS |  | six months | 
| NEUROHORMONAL CHANGES |  | six months |